MedPath

AbbVie Limited

🇭🇰Hong Kong, China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

52

PPB:25
NMPA:14
SFDA:13

Drug Approvals

Brimonidine Tartrate and Timolol Maleate Eye Drops

Product Name
溴莫尼定噻吗洛尔滴眼液
Approval Number
国药准字HJ20140928
Approval Date
Oct 29, 2024
NMPA

Carboxymethylcellulose Sodium Eye Drops

Product Name
羧甲基纤维素钠滴眼液
Approval Number
国药准字HJ20140945
Approval Date
Aug 26, 2024
NMPA

Carboxymethylcellulose Sodium Eye Drops

Product Name
潇莱威
Approval Number
国药准字HJ20140946
Approval Date
Aug 26, 2024
NMPA

Fluorometholone Eye Drops

Product Name
艾氟龙
Approval Number
国药准字HJ20130754
Approval Date
Aug 29, 2023
NMPA

Prednisolone Acetate Ophthalmic Suspension

Product Name
百力特
Approval Number
国药准字HJ20171243
Approval Date
Nov 4, 2022
NMPA

Prednisolone Acetate Ophthalmic Suspension

Product Name
百力特
Approval Number
国药准字HJ20171244
Approval Date
Nov 4, 2022
NMPA

Botulinum Toxin Type A for Injection

Product Name
保妥适
Approval Number
国药准字SJ20171005
Approval Date
Jun 14, 2022
NMPA

Botulinum Toxin Type A for Injection

Product Name
保妥适
Approval Number
国药准字SJ20171003
Approval Date
Jun 14, 2022
NMPA

Botulinum Toxin Type A for Injection

Product Name
保妥适
Approval Number
国药准字SJ20171004
Approval Date
Jun 14, 2022
NMPA

Brimonidine Tartrate Eye Drops

Product Name
阿法根
Approval Number
国药准字HJ20160681
Approval Date
Jun 28, 2021
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.